Veopoz® (pozelimab-bbfg)

Veopoz is covered only for FDA‑approved treatment of CD55‑deficient protein‑losing enteropathy (CHAPLE) in patients ≥1 year with genetic confirmation of a biallelic CD55 loss‑of‑function mutation; other indications, patients <1 year, or those with a history of meningococcal infection are excluded. Coverage requires serum albumin ≤3.2 g/dL, active disease within the past 6 months, up‑to‑date ACIP meningococcal, pneumococcal and Hib vaccinations, prescription by a physician experienced in CHAPLE, initial approval for 3 months (30 mg/kg IV loading dose then 10 mg/kg SC weekly maintenance with possible escalation to 12 mg/kg and a 800 mg weekly max), and reauthorization (12 months) only with documented clinical response.

"Initial authorization requirement: Does not have a history of meningococcal infection."

Sign up to see full coverage criteria, indications, and limitations.